Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients
InSightec
InSightec
Jazz Pharmaceuticals
National Institutes of Health Clinical Center (CC)
SonoClear AS
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Duke University
Columbia University
IRCCS Ospedale San Raffaele
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Institut Cancerologie de l'Ouest
Fundación de investigación HM
Black Diamond Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
Northwell Health
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Seattle Children's Hospital
University of California, San Francisco
NaviFUS Corporation
Nationwide Children's Hospital
National Cancer Institute (NCI)
Tango Therapeutics, Inc.
Mayo Clinic
University of Alabama at Birmingham
NaviFUS Corporation
NaviFUS Corporation
National Institutes of Health Clinical Center (CC)
NaviFUS Corporation
Nationwide Children's Hospital
Nationwide Children's Hospital
National Cancer Institute (NCI)
Mayo Clinic
Children's Oncology Group
Alpha Tau Medical LTD.
Medical University of Warsaw
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
Fore Biotherapeutics
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)